Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Arix Bioscience plc
  6. Summary
    ARIX   GB00BD045071

ARIX BIOSCIENCE PLC

(ARIX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensus 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
01/20/2022 01/21/2022 01/24/2022 01/25/2022 01/26/2022 Date
129(c) 127(c) 122(c) 122(c) 124.52 Last
207 527 102 735 171 204 143 398 50 943 Volume
-0.39% -1.55% -3.94% 0.00% +2.07% Change
More quotes
Estimated financial data (e)
Sales 2021 - - -
Net income 2021 - - -
Net cash position 2021 133 M 180 M 180 M
P/E ratio 2021 -
Yield 2021 -
Sales 2022 - - -
Net income 2022 - - -
Net cash position 2022 145 M 195 M 195 M
P/E ratio 2022 -
Yield 2022 -
Capitalization 151 M 204 M 204 M
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 12
Free-Float -
More Financials
Company
Arix Bioscience plc is a United Kingdom-based venture capital company that is focused on investing in and building biotechnology companies around advances in life sciences. The Company is a holding company that is focused on generating value from the development and commercialization of technologies and discoveries. The Company's principal activity is to source, finance and develop healthcare and life science... 
More about the company
Ratings of Arix Bioscience plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D
More Ratings
All news about ARIX BIOSCIENCE PLC
2021Sorriso Pharmaceuticals, Inc. announced that it has received $31 million in funding fro..
CI
2021Sorriso Pharmaceuticals, Inc. announced that it expects to receive $31 million in fundi..
CI
2021Arix Bioscience's Investee Raises $34 Million Via Oversubscribed Funding Round
MT
2021Depixus SAS announced that it has received €30.6 million in funding from Lansdowne..
CI
2021Arix Bioscience Unit Autolus Partners With Blackstone To Develop Cancer Therapies
MT
2021Arix Bioscience's Portfolio Firm Aura Biosciences Prices Nasdaq IPO
MT
2021ARIX BIOSCIENCE : Cancels Share Repurchase Program to Focus on Investments
MT
2021Tranche Update on Arix Bioscience plc's Equity Buyback Plan announced on March 15, 2021..
CI
2021Arix Bioscience plc's Equity Buyback announced on March 15, 2021, has expired with 6,42..
CI
2021ARIX BIOSCIENCE : Investee Aura Biosciences Posts Interim Data from Choroidal Melanoma Dru..
MT
2021ARIX BIOSCIENCE : Investee Pyxis Oncology Raises $167.2 Million in US IPO
MT
2021FTSE 100 Closes Down on Fears of Rising Consumer Costs
DJ
2021FTSE Drops, Sterling Expected to Gain on Prospect of Rate Rise
DJ
2021ARIX BIOSCIENCE : Makes Interim CEO Permanent
MT
2021ARIX BIOSCIENCE : Portfolio Company Artios Pharma Doses First Patient in Polymerase Theta ..
MT
More news
News in other languages on ARIX BIOSCIENCE PLC
2021L'entreprise dans laquelle investit Arix Bioscience lève 34 millions de dollars via un ..
2021Autolus, unité d'Arix Bioscience, s'associe à Blackstone pour développer des thérapies ..
2021Aura Biosciences, une entreprise du portefeuille d'Arix Bioscience, fait son entrée en ..
2021Arix Bioscience annule son programme de rachat d'actions pour se concentrer sur les inv..
2021Aura Biosciences, société dans laquelle investit Arix Bioscience, publie des données in..
More news
Chart ARIX BIOSCIENCE PLC
Duration : Period :
Arix Bioscience plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARIX BIOSCIENCE PLC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 122,00 GBX
Average target price 256,00 GBX
Spread / Average Target 110%
Managers and Directors
Robert William Henry Lyne CEO, COO, Secretary, Director & General Counsel
Marcus Karia Group Finance Director
Peregrine D. E. M. Moncreiffe Non-Executive Chairman
Graeme Smith Chief Technology Officer
Michael William Bunbury Senior Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ARIX BIOSCIENCE PLC0.00%204
BLACKROCK, INC.-12.78%121 128
BROOKFIELD ASSET MANAGEMENT INC.-11.02%84 528
BLACKSTONE INC.-14.80%78 371
UBS GROUP AG3.11%63 469
BANK OF NEW YORK MELLON CORPORATION (THE)1.62%47 461